| The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579 R Hoffmann, GS Baillie, SJ MacKenzie, SJ Yarwood, MD Houslay The EMBO journal 18 (4), 893-903, 1999 | 322 | 1999 |
| Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene BG BOLGER, S ERDOGAN, ER JONES, K LOUGHNEY, G SCOTLAND, ... Biochemical Journal 328 (2), 539-548, 1997 | 224 | 1997 |
| cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation … R HOFFMANN, IR WILKINSON, JF McCALLUM, P ENGELS, ... Biochemical Journal 333 (1), 139-149, 1998 | 186 | 1998 |
| Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor D Merkle, R Hoffmann Cellular signalling 23 (3), 507-515, 2011 | 125 | 2011 |
| The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma … DJP Henderson, A Byrne, K Dulla, G Jenster, R Hoffmann, GS Baillie, ... British journal of cancer 110 (5), 1278-1287, 2014 | 61 | 2014 |
| Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer H Bon, K Wadhwa, A Schreiner, M Osborne, T Carroll, A Ramos-Montoya, ... Molecular Cancer Research 13 (4), 620-635, 2015 | 60 | 2015 |
| Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease … R Böttcher, DJP Henderson, K Dulla, D van Strijp, LF Waanders, G Tevz, ... British Journal of Cancer 113 (10), 1502-1511, 2015 | 30 | 2015 |
| The enigmatic helicase DHX9 and its association with the hallmarks of cancer C Gulliver, R Hoffmann, GS Baillie Future Science OA 7 (2), FSO650, 2020 | 29 | 2020 |
| Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases R Böttcher, K Dulla, D van Strijp, N Dits, EI Verhoef, GS Baillie, ... Oncotarget 7 (43), 70669, 2016 | 26 | 2016 |
| Contrast agents for detecting prostate cancer R Hoffmann US Patent App. 12/446,463, 2010 | 26 | 2010 |
| The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus AM Byrne, C Elliott, R Hoffmann, GS Baillie FEBS letters 589 (6), 750-755, 2015 | 22 | 2015 |
| Use of a Composite or Composition of Diamond and Other Material for Analysis of Analytes P Bachmann, V Van Elsbergen, R Hoffmann, H Hummel, C Ribbing, ... US Patent App. 11/568,191, 2007 | 20 | 2007 |
| Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression WFJ Verhaegh, A Van De Stolpe, HJ Van Ooijen, KC Dulla, MA De Inda, ... US Patent 11,443,831, 2022 | 19 | 2022 |
| Differential distribution of rat PDE-7 mRNA in embryonic and adult rat brain R Hoffmann, S Abdel'Al, P Engels Cell biochemistry and biophysics 28, 103-113, 1998 | 15 | 1998 |
| Validation of cyclic adenosine monophosphate phosphodiesterase-4D7 for its independent contribution to risk stratification in a prostate cancer patient cohort with longitudinal … MA de Inda, D van Strijp, E den Biezen-Timmermans, A van Brussel, ... European Urology Focus 4 (3), 376-384, 2018 | 13 | 2018 |
| System, device, method, computer-readable medium, and use for in vivo imaging of tissue in an anatomical structure LP Bakker, MC Van Beek, MB Van Der Mark, R Van Den Ham, ... US Patent App. 12/515,023, 2010 | 12 | 2010 |
| In Vivo Expression Profiling R Hoffmann, H Hummel, M Wendt US Patent App. 11/916,548, 2008 | 12 | 2008 |
| Creating a potential diagnostic for prostate cancer risk stratification (InformMDx™) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase … DJP Henderson, MD Houslay, CH Bangma, R Hoffmann Clinical Science 133 (2), 269-286, 2019 | 10 | 2019 |
| The prognostic PDE4D7 score in a diagnostic biopsy prostate cancer patient cohort with longitudinal biological outcomes D Van Strijp, C De Witz, PC Vos, E den Biezen-Timmermans, ... Prostate Cancer 2018, 2018 | 10 | 2018 |
| Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy H Hummel, VU Weiler, R Hoffmann US Patent App. 11/721,382, 2009 | 10 | 2009 |
